Headlines about GlycoMimetics (NASDAQ:GLYC) have trended positive this week, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GlycoMimetics earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.5784107648202 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of GlycoMimetics (NASDAQ:GLYC) traded down 4.28% during trading on Thursday, reaching $12.53. The company had a trading volume of 340,367 shares. The stock has a 50 day moving average price of $12.62 and a 200 day moving average price of $10.02. GlycoMimetics has a 12 month low of $3.82 and a 12 month high of $16.94. The firm’s market capitalization is $410.02 million.
GlycoMimetics (NASDAQ:GLYC) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.30) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.07. On average, equities research analysts forecast that GlycoMimetics will post ($1.22) EPS for the current year.
In other news, SVP Helen M. Thackray sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $13.00, for a total transaction of $26,000.00. Following the sale, the senior vice president now directly owns 150,615 shares in the company, valued at $1,957,995. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 43.80% of the company’s stock.
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.
What are top analysts saying about GlycoMimetics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlycoMimetics Inc. and related companies.